Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
Gritstone fails to convince
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
